ERBB2 and breast carcinoma: In recent years, to reduce treatment costs and improve drug accessibility, the biosimilars of trastuzumab have been approved to treat HER2-positive breast cancer, such as anqutuo, herzuma, trazimera, tuznue, and so on [36,37,38,39].